ArticleCommunications biology2024
Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation.
Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria.NPJ biofilms and microbiomes · 2026Trial
- Distinct anthelmintic classes do not affect gut bacteria, and bacteria do not alter nematocidal efficacy inmicroPublication biology · 2026Article
- One Health, One Microbiome.Microbiome · 2025Review
- Exposure of gut bacterial isolates to the anthelminthic drugs, ivermectin and moxidectin, leads to antibiotic-like phenotypes of growth inhibition and adaptation.Communications biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Due to their broad-spectrum activities, ivermectin and moxidectin are widely used anthelminthics in veterinary and human medicine. However, ivermectin has recently been shown to perturbate bacterial growth. Given the macrolide-like structure of both ivermectin and moxidectin, there is a need to characterize the antibiotic spectrum of these anthelminthics and their potential implications in the development of cross-resistance to macrolides and other families of antibiotics. Here, we characterize growth dynamics of 59 bacterial isolates in presence of ivermectin and moxidectin. Further, we assessed the effect of repeated anthelminthic exposure in 5 bacterial isolates on sensitivity to different antibiotics, both via growth dynamics and minimal inhibitory concentration. We found, that anthelminthic growth phenotypes are comparable to a selection of tested antibiotics. Bacterial anthelminthic challenging resulted in decreased anthelminthic sensitivity, and to some extent, decreased antibiotic sensitivity. Hence, potential off-target effects of large-scale administration of ivermectin and moxidectin should be carefully monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.